TG Therapeutics, Inc.
TGTX
$48.74
$0.801.67%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 17.28% | 6.41% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 17.28% | 6.41% | |||
| Cost of Revenue | 22.93% | -12.14% | |||
| Gross Profit | 16.18% | 10.99% | |||
| SG&A Expenses | -6.90% | 40.60% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 28.53% | 19.74% | |||
| Operating Income | -37.71% | -31.09% | |||
| Income Before Tax | -49.74% | -54.84% | |||
| Income Tax Expenses | 318.60% | -97.34% | |||
| Earnings from Continuing Operations | -60.66% | -14.15% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -60.66% | -14.15% | |||
| EBIT | -37.71% | -31.09% | |||
| EBITDA | -37.61% | -31.06% | |||
| EPS Basic | -59.90% | -15.02% | |||
| Normalized Basic EPS | -64.68% | -35.21% | |||
| EPS Diluted | -58.33% | -14.65% | |||
| Normalized Diluted EPS | -64.70% | -34.79% | |||
| Average Basic Shares Outstanding | -1.85% | 1.03% | |||
| Average Diluted Shares Outstanding | -1.74% | 0.44% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||